Press Releases
Merck receives positive CHMP opinion for Zepatier in the EU
Merck announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending...
Press Releases
U.S. FDA Approves CSL Behring’s AFSTYL for adults and children with haemophilia A
CSL announced that the US Food and Drug Administration (FDA) has approved AFSTYLA® , CSL Behring’s novel long-lasting recombinant factor VIII single-chain therapy for...
News
Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Ian Read, Chairman and CEO at the...
News
AbbVie to Present at the Jefferies 2016 Healthcare Conference
AbbVie will participate in the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016. Bill Chase, executive vice president and chief financial officer, will...
Press Releases
GSK, Fondazione Telethon and Ospedale San Raffaele announce publication of pivotal safety and efficacy of gene therapy for children with ADA-SCID
GSK, Fondazione Telethon and Ospedale San Raffaeletoday announced the publication in BLOOD of the long-term safety and efficacy data from an analysis of 18...
Press Releases
Daiichi Sankyo Launches Antiplatelet Agent Efient® Tablets 20mg
Daiichi Sankyo Company, Limited announced that it has launched the antiplatelet agent Efient® Tablets 20mg (JAN: Prasugrel Hydrochloride; approval to market: January 20, 2016;...
Industry Reports
Thunderbolt Pharma, Inc , Vitesse Biologics Company, Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma Inc.
Baxalta Incorporated , Velocity Pharmaceutical Development, LLC and Astellas Pharma Inc announced that Thunderbolt, Inc., a company established by Vitesse Biologics, acquired all rights...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read